Mediscience nears tests for optical detector in US cervical cancer trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Mediscience Technology the all-clear to begin a multicentre pilot trial of its cervical cancer detector, a fluorescence-based optical device called the Cancer Diagnostic-Ratiometer (CD-R). The study will aim to determine the device's efficacy at distinguishing between tissues that are normal, benign, precancerous low grade, precancerous high grade, carcinoma in situ and cancer; the device's real-time results will be compared with those for Pap tests and biopsies. It will also assess any adverse events. Last month, Cherry Hill, New Jersey-based Mediscience said that it had teamed up with New York firm Alfanix Technology to construct the CD-R and other photonics devices for cancer diagnostics, and to introduce the devices into Latin America for testing on humans.